Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of between $250,000,000 and $255,000,000 that we provided on our last earnings call. As compared to the midpoint of our prior guidance range, approximately half of the overachievement in the quarter was due to constant currency performance, while the other half was due to foreign exchange be ...

Financial Data and Key Metrics Changes - The company reported total revenues of $197.1 million for Q1 2025, representing a year-over-year increase of 43% on an as-reported basis and 32% on an organic basis [7][29] - Adjusted non-GAAP EBITDA was $50.7 million, compared to $37.6 million in the prior year period, reflecting strong operational performance [33] - Adjusted non-GAAP EPS for the quarter was $1.70, up from $1.21 in the prior year [33] Business Line Data and Key Metrics Changes - Revenues from the rare disease segment were $69 million, up 87% from the prior year, driven by strong performance of Cortrophin Gel, which generated $52.9 million in revenues, a 43% increase [30][33] - The generics segment reported revenues of $98.7 million, an increase of 41% year-over-year, attributed to new product launches and strong execution in the base business [14][31] - Revenues from the brands portfolio were $25.1 million, a decrease of 2% from the prior year, indicating a return to more normalized demand levels [30] Market Data and Key Metrics Changes - The overall ACTH category grew 27% to approximately $684 million in 2024, with Cortrophin Gel capturing a significant share of new prescribers [9][10] - The company expects Cortrophin Gel revenues to increase by 34% to 38% in 2025, reaching $265 million to $274 million [10][36] - The retina products, ILUVIEN and YUTIQ, generated revenues of $16.1 million in Q1, with expectations of $97 million to $103 million for the full year [10][36] Company Strategy and Development Direction - The company is focused on expanding its rare disease business, particularly through Cortrophin Gel, and is investing in new clinical trials to support its growth trajectory [20][28] - A strategic emphasis is placed on enhancing market access for ILUVIEN and YUTIQ through specialty pharmacies and Medicare Part D options [23][24] - The company is committed to maintaining a strong U.S. manufacturing footprint, with over 90% of revenues coming from domestically produced goods [16][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Cortrophin Gel, citing a significant unmet medical need and a large addressable market [19][20] - The company anticipates a return to sequential revenue growth in the latter half of 2025, following a modest decline in Q2 [36] - Management acknowledged challenges in the retina segment due to market access issues but remains optimistic about recovery and growth in the second half of the year [11][56] Other Important Information - The company raised its 2025 guidance for total revenues and adjusted non-GAAP EBITDA based on strong Q1 performance and favorable demand trends [7][36] - The company has a strong balance sheet with $149.8 million in unrestricted cash and a gross leverage ratio of 3.5 times [33][34] - The company is preparing for an upcoming trial against CG Oncology regarding a royalty obligation dispute [38][39] Q&A Session Summary Question: How much should the prefilled syringe help Cortrophin? - Management noted that early responses to the prefilled syringe have been positive, as it reduces administration steps, and they expect to update on its progress soon [44] Question: What gives confidence in accelerating ILUVIEN and YUTIQ sales? - Confidence is based on performance outside the U.S., improvements in the sales force, and positive April results from a bespoke commercial approach [54][56] Question: Can you elaborate on the commercial challenges impacting ILUVIEN? - Challenges stemmed from a lack of funding for co-pay support for Medicare patients, affecting access to therapy [62] Question: What indications are driving growth for Cortrophin? - Growth is seen across all specialties, with significant contributions from nephrology, rheumatology, and ophthalmology [88] Question: How does the company view the acquisition of Alimera? - Management remains confident in the long-term opportunity for ILUVIEN and YUTIQ, as evidenced by the recent buyout of a royalty obligation [82]

FTAI Infrastructure (FIP) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good day, and welcome to the First Quarter twenty twenty five FTAI Infrastructure Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Instructions will be given at that time. As a reminder, this call is being recorded. I would now like to turn the call over to Alan Andrini, Investor Relations. Please go ahead. Speaker ...

Financial Data and Key Metrics Changes - The company reported a 38% year-over-year revenue growth in the first quarter of 2025, achieving $280 million in directional revenue guidance for the year [6][20] - Cash flow from operations reached a record $19.7 million [6] - The company aims to generate approximately $232 million in revenue over the remaining three quarters of the year [6] Business Line Data and Key Metrics Changes - Vevi revenue increased by 35% sequentially from $16 million in Q4 2024 to $21.5 million in Q1 2025, prior to the launch of the VIVI Access for All program [7][12] - iHizo's sales were impacted by destocking in Q1 2025, but unit sales more than doubled in April compared to the monthly average in Q1 [15][16] - Triassence completed critical market access initiatives in Q1, leading to a doubling of accounts ordering the product since the beginning of the year [18][19] Market Data and Key Metrics Changes - The company noted seasonality in its business, with Q1 typically being the weakest revenue period [9] - The specially branded products faced challenges due to volatility in gross to net estimates, affecting recognizable revenue [10] Company Strategy and Development Direction - The company is focused on achieving and potentially exceeding its 2025 revenue guidance through various product lines, including Vevi, iHizo, and Triassence [6][20] - The VeeVai Access for All program is expected to significantly impact revenue growth, with the potential to become a leading product in the dry eye medication market [12][14] - The company is not planning to exit the compounding business, emphasizing its importance in building commercial relationships and credibility [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting revenue guidance, citing strong momentum in new prescriptions and refill rates for Vevi [11][21] - The company anticipates that the third quarter will see stronger numbers driven by compounding effects from new prescriptions [23] - Management acknowledged the need for improvement in certain product lines and plans to review current strategies [59] Other Important Information - The company expects to deliver over $50 million in revenue from iHizo in 2025, with significant growth anticipated [22] - The ImprimisRx compounding business is projected to deliver more than $80 million in revenue in 2025 [22] Q&A Session Summary Question: Price increase initiatives for iHizo - Management indicated that there were no significant price increases for iHizo, and some price decreases were implemented to enhance accessibility [26][29] Question: Project Beagle initiatives - Management clarified that Project Beagle focuses on transitioning Clarity C patients to Vevi, which is expected to be financially beneficial [30][32] Question: Sequential changes in iHizo - Management noted that unit demand is returning to growth mode, with expectations for incremental growth in Q2 [38][41] Question: Triassence volume inflection - Management reported that many new accounts are beginning to use Triassence, with positive signs of adoption in various care settings [44][46] Question: Impact of tariffs on products - Management estimated a negligible impact of current tariff policies on gross margins, around 50 basis points [68][70] Question: Debt refinancing plans - Management expressed confidence in successfully restructuring debt by late summer or early fall, with positive discussions ongoing with lenders [85][86]

TeraWulf (WULF) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Greetings and welcome to the TerraWolf twenty twenty five First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, John Larkin, Senior Vice President, Director of Investor Relations. Thank you, sir. You may begin. Speaker1 Thank y ...

Victory Capital (VCTR) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Victory Capital First Quarter twenty twenty five Earnings Conference Call. All callers are on a listen only mode. Following the company's prepared remarks, there will be a question and answer session. I will now turn the call over to Mr. Matthew Dennis, Chief of Staff and Director of Investor Relations. Please go ahead, Mr. Dennis. Speaker1 Thank you. Before I turn the call over to David Brown, I ...

Assured Guaranty (AGO) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Assured Guaranty Limited First Quarter twenty twenty five Earnings Conference Call. My name is Ezra, and I will be the operator for today's call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to our host, Robert Tucker, Senior Managi ...

Financial Data and Key Metrics Changes - GMV for Q1 2025 was $94.7 million, up 3% year over year, exceeding guidance despite a challenging market backdrop [22][32] - Net revenue increased to $22.5 million, a 2% rise, with transaction revenue comprising approximately 75% of total revenue [27][32] - Adjusted EBITDA loss was $1.7 million, compared to a loss of $1.8 million in the previous year, maintaining an adjusted EBITDA margin loss of 8% [30][32] Business Line Data and Key Metrics Changes - Consumer GMV grew mid-single digits, while trade GMV remained flat; jewelry and fashion verticals posted double-digit growth [25][32] - Active buyers increased to approximately 64,800, reflecting a 7% year-over-year growth [25][32] - Unique seller accounts decreased by 23% year over year to about 5,900, attributed to subscription pricing optimizations [19][26] Market Data and Key Metrics Changes - The company experienced steady listings growth, ending the quarter with over 1.8 million listings, up 5% [26][32] - Organic traffic accounted for over 70% of total traffic, with improvements in SEO and direct traffic contributing to growth [12][24] - Conversion rates improved year over year for six consecutive quarters, although growth moderated in Q1 compared to Q4 [10][24] Company Strategy and Development Direction - The company is focused on a product-led growth strategy aimed at enhancing buyer and seller experiences while gaining market share [4][10] - Key initiatives include accelerating organic traffic growth, competitive pricing, funnel optimization, and elevating service levels [11][12] - The company aims to maintain growth and expense discipline while capturing additional market share throughout 2025 [20][33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a tougher demand backdrop for luxury home discretionary spending due to evolving trade policies and macroeconomic effects [5][8] - The company expects continued listings growth and normalization of seller churn in Q2 2025 [20][32] - Future guidance reflects a forecasted GMV of $85 million to $92 million for Q2, indicating a potential decline of 7% to an increase of 1% [31][32] Other Important Information - The company has repurchased approximately $33.4 million worth of shares since initiating its buyback program in August 2023 [31] - The adjusted EBITDA margin guidance for Q2 is projected to be a loss of 14% to 10%, reflecting increased headcount-related costs and transaction loss provisions [32] Q&A Session Summary Question: On organic traffic and conversion - Management noted that organic traffic had declined for over a year but returned to growth in Q1, attributing this to product and engineering efforts [36][38] - Conversion changes were primarily driven by macroeconomic factors, particularly in the consumer furniture segment [39][40] Question: On active buyers growth - Active buyer growth is linked to conversion rates, which are influenced by macroeconomic conditions; management remains focused on long-term value drivers [44][46] Question: On market share gains - Market share is measured against GMV changes versus syndicated credit card data, with growth observed for five consecutive quarters [50] - The rollout of machine learning pricing models has seen high adoption for lower-priced items, with ongoing improvements expected [52][54]

Financial Data and Key Metrics Changes - The company reported a consolidated GAAP net loss of $62 million or a negative $1.28 per share for Q1 2025, compared to a net loss of $86 million or a negative $1.84 per share for Q1 2024, indicating an improvement in financial performance [9][10] - The adjusted net loss for Q1 2025 was $8 million or a negative $0.16 per share, compared to an adjusted net loss of $24 million or a negative $0.52 per share for Q1 2024, reflecting a favorable change primarily due to lower losses in LAE [12][13] - The book value per share decreased by $1.23 to a negative $42.22 as of March 31, 2025, from a negative $40.99 as of December 31, 2024, primarily due to the consolidated net loss [13] Business Line Data and Key Metrics Changes - National reported statutory net income of $4 million for Q1 2025, compared to a statutory net loss of $11 million for Q1 2024, driven by lower losses in LAE related to PREPA exposure [15][16] - MBIA Insurance Corp reported statutory net income of $2 million for Q1 2025, compared to a statutory net loss of $35 million for Q1 2024, also due to lower losses in LAE [16][17] - The gross par amount outstanding for National's insured portfolio declined by approximately $500 million from year-end 2024 to about $25 billion as of March 31, 2025 [7] Market Data and Key Metrics Changes - National's leverage ratio of gross par to statutory capital was 27 to 1 at the end of Q1 2025, with total claims paying resources of $1.5 billion and statutory capital surplus exceeding $900 million [8] Company Strategy and Development Direction - The company continues to prioritize resolving National's PREPA exposure, which remains uncertain, and believes that reducing uncertainty regarding PREPA is essential for maximizing shareholder value [7] - The management expressed optimism about the potential resolution of the PREPA situation, indicating that the focus is shifting towards addressing key litigation issues [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the complexity of the PREPA situation and emphasized ongoing discussions in Washington, D.C., while expressing cautious optimism about moving into a different phase regarding the resolution [22][24] - The overall portfolio performance is consistent with expectations, with no significant concerns regarding other credits [25] Other Important Information - The corporate segment had total assets of approximately $685 million as of March 31, 2025, including unencumbered cash and liquid assets totaling $378 million [14] Q&A Session Summary Question: What is being done politically to resolve the PREPA situation? - Management highlighted that fixing PREPA is a top priority for Governor Gonzalez and that there are ongoing conversations in D.C. to facilitate resolution, with optimism about moving into a different phase [22][24] Question: Are there concerns about further write-offs in the National portfolio? - Management confirmed that the portfolio is performing within expectations and that PREPA is the primary focus, with no significant concerns about other credits [25]

Brighthouse Financial (BHF) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to Brighthouse Financial's First Quarter twenty twenty five Earnings Conference Call. My name is Michelle, and I will be your coordinator today. At this time, all participants are in a listen only mode. We will facilitate a question and answer session towards the end of the conference call. In fairness to all participants, please limit yourself to one question and one follow-up ...